Researchers from UC San Diego found that children diagnosed with metabolic dysfunction-associated steatotic liver disease (MASLD) are at significantly increased risk of premature death and serious long-term health complications. The study, which followed 1,096 children over an average of 8.5 years. Nearly half of all deaths in the cohort were liver-related, and the overall mortality rate was 40 times higher than that of similar peers in the general U.S. population.

Teams of health care providers called Accountable Care Organizations participating in the Medicare Shared Savings Program have saved Medicare between $4.1 billion and $8.1 billion from 2012 through 2019, according to a new study from Weill Cornell Medicine investigators. The study, published April 28 in JAMA, is thought to be the first to investigate the long-term impact of the program.

Matthew Sacchet, PhD, Director of the Meditation Research Program at Massachusetts General Hospital and an Associate Professor of Psychiatry at Harvard Medical School, is senior author of a paper in Clinical Psychological Science, “Risk Factors for Emergence of Sudden Unusual Mental or Somatic Experiences and Subsequent Suffering.”

CommunityRx-Hunger, a low-intensity program that “prescribes” a list of community social care resources during a child's hospital discharge, lowered emergency room visits for food-insecure families and potentially saved healthcare costs.

About The Study: Cohort-specific patterns across states reveal wide disparities in mortality. Some states have experienced little or no improvements in life expectancy from the 1900 to 2000 birth cohorts. Understanding how mortality patterns vary by birth cohort within each state can inform decision-making around resource allocation and public health interventions.

About The Study: The results of this study suggest that maternal health was difficult to track due to changes in reporting practices, but public health emergencies such as the COVID-19 pandemic can have large negative impacts.

Three investigators and their teams have each received €100,000 funding for clinical trial development projects as part of the International Progressive MS Alliance’s Experimental Medicine Trial Awards. These development studies are for planning, developmental efforts, and/or validation opportunities with a goal of growing into full clinical trials to help us better understand MS progression and find new treatments for the disease.